Ligand Pharmaceuticals Incorporated

LGND

US53220K5048

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
98 ^USD	+1.77%		+18.50%	+37.22%

Jul. 08	Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties	MT
Jul. 08	Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024	CI

Invios GmbH announced that it expects to receive $4 million in funding from Ligand Pharmaceuticals Incorporated

July 07, 2024

Invios GmbH announced that it will receive $4 million from new investor Ligand Pharmaceuticals Incorporated on July 8, 2024. The transaction expected to close in July 2024.

Latest news about Ligand Pharmaceuticals Incorporated

Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties	Jul. 08	MT
Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024	Jul. 08	CI
Ligand Pharmaceuticals Incorporated entered into an agreement to acquire APEIRON Biologics AG for $128 million.	Jul. 07	CI
Invios GmbH announced that it expects to receive $4 million in funding from Ligand Pharmaceuticals Incorporated	Jul. 07	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Defensive Index	Jun. 30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 3000 Growth Index	Jun. 30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Value-Defensive Index	Jun. 30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 3000E Growth Index	Jun. 30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2000 Growth Index	Jun. 30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2500 Growth Index	Jun. 30	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell Small Cap Comp Growth Index	Jun. 30	CI
Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease	Jun. 27	MT
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	Jun. 18	MT
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults	Jun. 18	CI
Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing	May. 13	MT
Sector Update: Health Care Stocks Softer Late Afternoon	May. 08	MT
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views	May. 08	MT
Transcript : Ligand Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M	May. 07	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83	May. 07	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024	May. 07	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	May. 07	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	Apr. 08	CI

Chart Ligand Pharmaceuticals Incorporated

Duration

Period

Chart Ligand Pharmaceuticals Incorporated

More charts

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Sector

Pharmaceuticals

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ligand Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

98 USD

Average target price

117.8 USD

Spread / Average Target

+20.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIGAND PHARMACEUTICALS INCORPORATED	+37.22%	1.76B
ELI LILLY AND COMPANY	+60.25%	841B
NOVO NORDISK A/S	+39.01%	625B
JOHNSON & JOHNSON	-4.49%	360B
MERCK & CO., INC.	+18.30%	327B
ABBVIE INC.	+9.64%	300B
ASTRAZENECA PLC	+15.79%	242B
ROCHE HOLDING AG	+3.72%	228B
NOVARTIS AG	+17.90%	227B
AMGEN INC.	+12.87%	174B

Other Pharmaceuticals

Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Pharmaceuticals

Invios GmbH announced that it expects to receive $4 million in funding from Ligand Pharmaceuticals Incorporated

Latest news about Ligand Pharmaceuticals Incorporated

Chart Ligand Pharmaceuticals Incorporated

Company Profile

Income Statement Evolution

Ratings for Ligand Pharmaceuticals Incorporated

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals